HRP20140591T1 - Poboljšani medicinski pripravci koji sadrže buprenorfin i nalmefen - Google Patents

Poboljšani medicinski pripravci koji sadrže buprenorfin i nalmefen Download PDF

Info

Publication number
HRP20140591T1
HRP20140591T1 HRP20140591AT HRP20140591T HRP20140591T1 HR P20140591 T1 HRP20140591 T1 HR P20140591T1 HR P20140591A T HRP20140591A T HR P20140591AT HR P20140591 T HRP20140591 T HR P20140591T HR P20140591 T1 HRP20140591 T1 HR P20140591T1
Authority
HR
Croatia
Prior art keywords
buprenorphine
nalmefene
medicinal compositions
dosage form
unit dosage
Prior art date
Application number
HRP20140591AT
Other languages
English (en)
Croatian (hr)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Rb Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rb Pharmaceuticals Limited filed Critical Rb Pharmaceuticals Limited
Publication of HRP20140591T1 publication Critical patent/HRP20140591T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20140591AT 2007-03-01 2008-02-15 Poboljšani medicinski pripravci koji sadrže buprenorfin i nalmefen HRP20140591T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0703933A GB2447013A (en) 2007-03-01 2007-03-01 Analgesic composition containing buprenorphone and nalmefene
PCT/GB2008/000522 WO2008104736A1 (en) 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and nalmefene

Publications (1)

Publication Number Publication Date
HRP20140591T1 true HRP20140591T1 (hr) 2014-09-12

Family

ID=37965707

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20140591AT HRP20140591T1 (hr) 2007-03-01 2008-02-15 Poboljšani medicinski pripravci koji sadrže buprenorfin i nalmefen

Country Status (21)

Country Link
US (1) US8497280B2 (enExample)
EP (1) EP2114452B1 (enExample)
JP (1) JP5577102B2 (enExample)
KR (1) KR101437461B1 (enExample)
CN (1) CN101622012B (enExample)
AR (1) AR065582A1 (enExample)
AU (1) AU2008220572B2 (enExample)
BR (1) BRPI0807903A2 (enExample)
CA (1) CA2678568C (enExample)
CL (1) CL2008000607A1 (enExample)
DK (1) DK2114452T3 (enExample)
ES (1) ES2476865T3 (enExample)
GB (1) GB2447013A (enExample)
HR (1) HRP20140591T1 (enExample)
MX (1) MX2009009134A (enExample)
PE (2) PE20120956A1 (enExample)
PL (1) PL2114452T3 (enExample)
PT (1) PT2114452E (enExample)
TW (1) TWI468163B (enExample)
WO (1) WO2008104736A1 (enExample)
ZA (1) ZA200905692B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
CN102459276B (zh) * 2009-05-25 2016-09-21 H.隆德贝克有限公司 从纳曲酮制备盐酸纳美芬
EP2844236B1 (en) 2012-04-17 2018-12-19 Purdue Pharma LP Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN103637983B (zh) * 2013-12-16 2017-08-04 科贝源(北京)生物医药科技有限公司 一种含有盐酸纳美芬的药物组合物及其制备方法
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN104922061B (zh) * 2015-05-26 2017-09-22 成都天台山制药有限公司 盐酸纳美芬注射液药物组合物和制法
CA3068036A1 (en) 2017-06-30 2019-01-03 Purdue Pharma L.P. Use to buprenorphine in combination with an opioid to treat pain
AU2019224084A1 (en) * 2018-02-22 2020-09-10 Avior, Inc. Transmucosal film composition and methods of making and using the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
WO1999032120A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
EP2049139A4 (en) * 2006-04-24 2009-06-24 Gloucester Pharmaceuticals Inc TREATMENT OF TUMORS EXPRESSING RAS
WO2007146730A2 (en) * 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
US20110015168A1 (en) * 2007-01-19 2011-01-20 Mitchell Keegan Methods for increasing levels of human fetal hemoglobin

Also Published As

Publication number Publication date
JP5577102B2 (ja) 2014-08-20
GB0703933D0 (en) 2007-04-11
PE20120956A1 (es) 2012-08-01
KR101437461B1 (ko) 2014-09-05
DK2114452T3 (da) 2014-06-30
EP2114452A1 (en) 2009-11-11
TWI468163B (zh) 2015-01-11
KR20090115862A (ko) 2009-11-09
HK1139868A1 (en) 2010-09-30
CL2008000607A1 (es) 2008-10-03
US8497280B2 (en) 2013-07-30
CA2678568C (en) 2015-06-16
JP2010520184A (ja) 2010-06-10
PT2114452E (pt) 2014-07-15
ZA200905692B (en) 2010-10-27
AU2008220572B2 (en) 2014-03-27
BRPI0807903A2 (pt) 2014-06-17
PE20090625A1 (es) 2009-06-04
CN101622012B (zh) 2012-05-30
EP2114452B1 (en) 2014-04-09
CN101622012A (zh) 2010-01-06
CA2678568A1 (en) 2008-09-04
AU2008220572A1 (en) 2008-09-04
GB2447013A (en) 2008-09-03
PL2114452T3 (pl) 2014-09-30
WO2008104736A1 (en) 2008-09-04
ES2476865T3 (es) 2014-07-15
US20100152222A1 (en) 2010-06-17
AR065582A1 (es) 2009-06-17
MX2009009134A (es) 2009-09-03
TW200900067A (en) 2009-01-01

Similar Documents

Publication Publication Date Title
HRP20140592T1 (hr) Poboljšani medicinski pripravci koji sadrže buprenorfin i naltrekson
MX2009009131A (es) Mejoras en y con relacion a composiciones medicinales.
HRP20140591T1 (hr) Poboljšani medicinski pripravci koji sadrže buprenorfin i nalmefen
EP2032128B1 (en) Use of substituted 2-aminotetralines for the manufacture of a medicament for the prevention, alleviation and/or treatment of various types of pain
JP2010520186A5 (enExample)
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
BRPI0518622A2 (pt) usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
BRPI0707235B1 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
WO2008027350A3 (en) Acetaminophen pharmaceutical compositions
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
NZ613291A (en) Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
GB0814302D0 (en) Compounds and methods
JP2010520183A5 (enExample)
NZ604662A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine
MX2009009133A (es) Composiciones medicinales mejoradas que comprenden buprenorfina y naloxona.
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
JP2013541583A5 (enExample)
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
JP2010520184A5 (enExample)
JP2016505050A5 (enExample)
NZ719087A (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
RU2011111792A (ru) Применение парацетамола и ибупрофена в лечении